ClinicalTrials.gg
CompletedNCT00171899Updated Feb 23, 2017

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

A Phase 4 interventional study of imatinib mesylate in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 open to participants now, 5 under way, none of them phase 3. imatinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
35th of 83
80 · median 60
Started
2005
with 6 others
Phase 4
8 of 93
1 open now
Registered
33rd of 93
by date
Lead sponsor
15 of 93
Novartis Pharmaceuticals

Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 35th largest by enrollment of the 83 interventional ones that give a count, is one of 7 that started in 2005, is one of 8 in phase 4, and was the 33rd registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

1 of the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The study will assess the role of high-dose imatinib mesylate, in patients who have taken imatinib mesylate for at least 1 year at the standard dose, in achieving a major molecular response (a measure of the level of chronic myelogenous leukemia) versus the standard dose.

03

Conditions studied

  • Chronic Myelogenous Leukemia

Keywords

  • Chronic Myelogenous Leukemia
  • Complete cytogenetic response
  • Imatinib mesylate
  • Major molecular response
  • Chronic phase Ph+ Chronic Myelogenous Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic myelogenous leukemia with Philadelphia chromosome
  • 18 years and older
  • Patients must have been taking imatinib mesylate standard dose for at least 12 months and have achieved a complete cytogenetic response but not a major molecular response.

Exclusion criteria

Exclusion Criteria:

  • Patients with cardiac problems such as congestive heart failure, or myocardial infarction within the last 6 months
  • Patients with an uncontrolled medical disease such as uncontrolled diabetes, chronic renal (kidney) disease or active uncontrolled infection.
  • Patients with other current primary or malignancy requiring active intervention

Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    STI571

    Drug: imatinib mesylate

Interventions

06

What researchers measure

Primary outcomes

  1. Percent of patients achieving major molecular response at baseline and at last visit

Secondary outcomes

  1. Complete cytogenetic response at baseline and at last visit

  2. Overall survival

  3. Disease progression-free survival

  4. Quality of Life assessment at baseline, last visit

  5. Safety: adverse events and lab parameters, vital signs, physical exam, electrocardiogram, concomitant medications

07

Study locations

1 site
  • Novartis Investigative Site
    Toronto, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 15, 2005
Start
Apr 2005
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Last update
Feb 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00171899
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Apr 2005
Primary completion
Jun 2007
Completion
Jun 2007
Last update
Feb 23, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion